Brief: Spyglass Pharma Inc - BIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027
18/05/2026 14:02
May 18 (Reuters) - SpyGlass Pharma Inc SGP.O: SPYGLASS PHARMA INC - BIM-IOL SYSTEM PHASE 3 TRIAL ENROLLMENT EXPECTED TO COMPLETE IN 2027 Source text: ID:nGNX12kskk Further company coverage: SGP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SpyGlass Pharma
See all newsBrief: Spyglass Pharma Announces Positive 4-Year Data From First-In-Human Trial Of BIM-Iol System
SpyGlass Pharma Q2 net loss widens on higher expenses
Brief: Spyglass Pharma Inc - BIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027
Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO (updated)
NASDAQ RESUMED AT 01:46 PM